RecruitingNCT03566797

Secondary Sclerosis Cholangitis Prospective

Secondary Sclerosing Cholangitis in Critically Ill Patients (SC-CIP): A Prospective Cohort Study

Sponsor

Medical University of Graz

Enrollment

380 participants

Start Date

Jul 20, 2018

Study Type

OBSERVATIONAL

Conditions

Secondary Sclerosis Cholangitis in Critically Ill Patients

Summary

SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the pathogenesis The aim of this project is to study gut microbiome composition, gut permeability, bacterial translocation, inflammation, bile acid composition and genetic polymorphisms by conducting a prospective cohort study in patients with a high risk to develop SC-CIP.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Participant is willing and able to give informed consent for participation in the study OR "surrogate consent" by the institutional review board.
Age above 18 years
Mechanical ventilation or extracorporeal membrane oxygenation \>/= 5 days

Exclusion Criteria1

Primary or secondary sclerosing cholangitis diagnosed before current ICU admission

Locations(1)

Medical University Graz

Graz, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03566797